Incidence of therapy switch in patients with moderate to severe palmoplantar psoriasis treated with anti-IL 17 and anti-IL 23 monoclonal antibodies: a retrospective observational study
This real-life evidence confirms the reduced necessity of therapy switch in patients with palmoplantar psoriasis treated with anti-IL 23 antibodies, compared to those treated with IL 17 inhibitors.
Authors
- Salvatore Panduri (ORCID: https://orcid.org/0000-0003-1383-498X)
- Cristian Fidanzi (ORCID: https://orcid.org/0000-0002-9189-9204)
- Alessandra Michelucci (ORCID: https://orcid.org/0000-0002-0795-0338)
- Flavia Manzo Margiotta (ORCID: https://orcid.org/0000-0002-9593-9357)
- Marco Romanelli (ORCID: https://orcid.org/0000-0002-4127-0141)
- Valentina Dini (ORCID: https://orcid.org/0000-0002-4639-3167)
- Riccardo Morganti (ORCID: https://orcid.org/0000-0001-7783-0262)
- Filippo Fanetti
- Brittany Chittano
Institutions
- University of Pisa (IT)
- Scuola Superiore Sant'Anna (IT)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1080/14712598.2025.2480756
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00